However, no human clinical studies have tested GHK-Cu for cognitive outcomes
Patients who took a high dose of tirzepatide lost 22.5% of their body weight on average, or 52 pounds, better than any medication currently on the market
& Hwang, S-S
ApoB is particularly useful in patients with hypertriglyceridemia, diabetes, metabolic syndrome, obesity, very low LDL-C on therapy, suspected discordance, premature ASCVD, or persistent risk despite apparently controlled LDL-C
Continuous, daily usage without breaks is generally not recommended due to the lack of extensive human data and potential risks 1 2
Serious adverse effects are extremely rare